-
Disease Description
Type 2 diabetes mellitus is a disorder affecting the way your body uses glucose (sugar). Cells in your body need sugar to work normally and sugar gets into the cells with the help of the hormone called insulin. Without enough insulin, or if the body stops responding to insulin, sugar builds up in the blood.[1]
In type 2 diabetes mellitus, the pancreas does not make enough insulin, the body becomes resistant to normal or even high levels of insulin, or both. This causes high blood glucose (blood sugar) levels, which can cause serious problems if untreated.[1]
Type 2 diabetes is a medical condition that requires regular monitoring and treatment throughout your life. Fortunately, with proper treatment one can keep blood sugar levels close to normal and minimize the risk of developing complications.[1]
Prevalence
In 2012, 29.1 million Americans, or 9.3% of the population, had diabetes. Diabetes remains the 7th leading cause of death in the United States in 2010, with 69,071 death certificates listing it as the underlying cause of death, and a total of 234,051 death certificates listing diabetes as an underlying or contributing cause of death. In the United States, Canada, and Europe, about 90 percent of all people with diabetes have type 2 diabetes.[2]
Current Treatment Options
Treatment includes lifestyle changes, self-care measures, and sometimes medications.A number of oral medicines (pills) are available to treat type 2 diabetes. [2]
Metformin — Most people who are newly diagnosed with type 2 diabetes will immediately begin a medicine called metformin (Glucophage, Glumetza, Riomet, Fortamet). Metformin improves how your body responds to insulin to reduce high blood sugar levels.[2]
Insulin — In the past, insulin treatment was reserved for patients with type 2 diabetes whose blood sugars were not controlled with oral medicines and lifestyle changes. However, there is increasing evidence that using insulin at earlier stages may improve overall diabetes control and help to preserve the pancreas's ability to make insulin.[2]
There are a number of additional medications on the market. You should consult with your health care provider to see which medications are right for you.
Evidence for and Proposed Mechanism for Cannabinoid Therapies
The study of the role of the endocannabinoids and their receptors in food intake and energy balance led, only little more than a decade after the identification of the endocannabinoid signaling system, to the development of several new therapeutic drugs. However due to unwanted side effects these drugs were eventually removed from the market.[3]
Rather than global obesity, often associated with depressive disorders, the indication novel cannabinoid compounds, as well as of other strategies aiming at reducing endocannabinoid overactivity, should be instead for those metabolic dysfunctions that are associated with abdominal obesity. For example, the administration of second-generation CB1 receptor antagonists to moderately obese patients is likely to improve considerably the benefit/risk ratio of these compounds and result in long-term beneficial outcomes on type 2 diabetes.[3]
1) UpToDate online resource
2) American Diabetes Association
3) Mechoulam et al. Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes
-
Category
Critical Ailments -
Created
Thursday, 16 March 2017 -
Group admin
CBIS
American States University
*** Warning this document contains graphic images.
Click the Below Image to Review our Cancer Drug Comparables
1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.
2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.
*** PLUS
(3) other Cannabis Science
REAL WORLD Successes:
Stage 4 Breast Cancer
Skin Cancer
Karposis Sarcoma
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Photos
Observational Studies
CSi-VIP & CBIS-Shareholder Legacy
Click the ABOVE Image to Review our 1-Million Strong FC, Media Kit
*** Warning this document contains exciting images. 
Please Click the above image for information to become a CSi-VIP & CSi-VIP Legacy Cancer Drug Owner
Pease Click the Calendar image to book your time to speak with Mr. Dabney about "Your Final CSi-VIP Shareholder Legacy".
Click the above Image to become one of the First 1-Million Strong Killing Cancers, Fight Club Members to help 'Make that Change' Join in Now! *** Warning this Membership contains Exciting Results.
PS ... ALL of our CSi-VIP's and those who Donated through the ASU/CSi-EDP GO-Fund-Me Promotion you do not need to purchase anything, you are ALREADY included in the "First" 1-Million Membership Club, CONGRATULATIONS !!!
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 2024, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2025 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2025
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,839,095,296
Fully Diluted:
4,510,547,648
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
Activity Stream
CONGRATULATIONS Guys! We are about to go LIVE! We are launching a very exciting New Chapter in our Journey! We are launching a very ambitious... Show more
-
-
3-
-
-
5-
1-
2